Pharma trends in bric economies

812 views

Published on

Published in: Business, Health & Medicine
0 Comments
1 Like
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total views
812
On SlideShare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
61
Comments
0
Likes
1
Embeds 0
No embeds

No notes for slide
  • They are expected to amount to nearly a third of the global pharmaceutical market by 2016, and it is anticipated that they will play a vital role in sustainable growth in the industry
  • Healthcare has emerged as one of the most progressive and largest service sectors in India.expected GDP spend of 8% in 2012, up from 5.5% in 2009.According to the McKinsey report India Pharma 2015—Unlocking the Potential of the Indian Pharmaceuticals Market, rural India contains more than 100 million untreatedpeople.However, the government is successfully pursuing its goal of providing 80% of the population with healthcare access in the next 15–20 years.last five years, the rural healthcare sector has seen the addition of 15,000 health sub-centers and 28,000 nurses. Likewise, the number of primary health centers has increased by 84%, taking the total number to 20,107.challenges remain. Doctors in 23 of India’s 28 states do not have to enroll in continuing education to stay certified. Sales reps’ pitches can sometimes be their only source of new information.Sales rep salaries are up, even while productivity is down. Due to increased competition.The Indian health insurance market has emerged and lucrative growth.Health insurance premiums are expected to grow at a CAGR of more than 25% for the period spanning from 2009 to 2014.
  • The Pharmaceutical Market:India’s pharmaceutical industry has the third largest volume in the world and ranks 14th in terms of value. It is expected to reach US$55 billion in 2020, from US$12.6 billion in2009.New developments in the local market include:• The arrival of new MNCs• Launch of patented products by existing MNCs• Growing number of in-licensing activities, both amongIndian companies and MNCs• Increased R&D investment by local companies• Fundraising conducted by local companies throughGlobal Depository Receipts or Foreign CurrencyConvertible Bonds to finance investments• Emergence of the hospital sector (according to industryestimates, India needs an additional 100,000 hospitalbeds every year for 10 years to meet demand)
  • Pharmaceutical companies in India face a range of challenges.India contains:• Approximately 60,000 unionized distributors andwholesalers• Between 400,000 and 500,000 chemists• Between 18,000 and 20,000 hospitals, which accountfor just 12% of the total market• 600,000 to 700,000 doctors who must serve the entirePopulation.The country’s market is also tempered by government enforced price controls and a jump in labor costs, which now equal up to 14–17% of sales for several major drugmakers.India is home to more than 30 times as many medicine brands as Europe and the US. About 90% of prescriptions are branded generics, and prices between the brands candiffer by as much as 75%. Indian doctors usually prescribe brand names rather than chemical names, making brand loyalty a key goal for drugmakers.
  • s China's National People's Congress ends in Beijing, Chinese politicians are repeating their pledge to make healthcare more affordable. Unfortunately for drugmakers, that means officials are also pledging to adopt Anhui province's aggressive tendering system, which slashed prices by at least 30% on key drugs over the past year.Anhui's drug-buying approach has attracted a lot of attention, from government officials impressed by the price cuts and from drugmakers wary of broader use. Already, some domestic pharma companies have had to slash margins to the bone--or even take a loss--to get Anhui's business. As Bloomberg notes, several have warned that their profits will drop because of the price cuts.Multinational drugmakers have joined Chinese pharma companies in lobbying against a nationwide rollout of Anhui's tendering methods. Big Pharma has pinned growth hopes onto expansion in China, investing in facilities and partnerships to expand its presence in the country. Large-scale price cuts could threaten those aspirations. Think how disheartening it would be for drugmakers to find China as intent on cost-cutting as the Europeans are now.Read more: Chinese officials intent on 'Anhui model' for price cuts - FiercePharma http://www.fiercepharma.com/story/chinese-officials-intent-anhui-model-price-cuts/2012-03-14#ixzz2cuIs90YE Subscribe at FiercePharmaAs a result of the 850 billion Chinese Yuan (CNY) health-care reform package implemented from 2009 to 2011, over 1.3 billion people – 95 per cent of the population – were covered by the end of 2011.in just three years, 172 million previously excluded people have been brought into the three health insurance schemes for i) urban employees, ii) rural residents and iii) non-employed urban resident
  • Pharma trends in bric economies

    1. 1. Mihir Pandit [PC-09] Bhakti Shethia [PC-20] Sneha Agarwal [QA-17] Jigar Raval [PA-08] Vipul Patil [PA-20] Trends in Pharma Emerging Markets: Today and Tomorrow
    2. 2. TAKING A FRESH LOOK AT EMERGING MARKET  Growth patterns in developed markets continue to flatten  Firms are shifting more of their focus- new sources of revenues and profitability in emerging markets  Reason for hope: Driven by increasing wealth and a growing awareness of the advantages of good healthcare and healthier lifestyles, emerging markets are developing into sources of significant growth.  “Promised land”  HELP: •Stagnation of mature markets •Patent expirations •Increased regulatory hurdles. Cluster 1 Cluster 2 Cluster 3 BRICMT economies Second-tier countries Southeast Asia Africa
    3. 3. PHARMACEUTICAL POTENTIAL OF EMERGING MARKET AND MATURE MARKET Source: IMS Health Market Prognosis; Global Insight; Booz & Company analysis PHARMACEUTICAL MARKETS PHARMA MARKET GROWTH (2011–12) VS. PHARMA MARKET SIZE (2012) The population of the individual countries is depicted by the size of the bubbles. Fastest emerging markets Developed markets
    4. 4. Volume market share by product class (Standard units): BRICS % of patients in BRIC countries who could afford high cost therapies in 2011 and 2015 Source: IMS MIDAS Q411 based on ethical market only.
    5. 5. BRAZIL
    6. 6. STATE OF THE HEALTHCARE SYSTEM • Health care spending around 9% of GDP • Free or reduced cost medicines for patients with chronic diseases by SUS • All the drugs to be kept behind the counter PHARMA MARKETS • 3rd largest pharmaceutical market in the Americas, after the US and Canada • Demand for pharmaceutical products growing by 10% per year • Expected to reach US $27 billion by 2015 • MNCs moving in- Eg. Amgen, Sanofi, Pzifer, Valeant • Local drug makers- massive detailing, opening up new R&D units Source: http://www.regulacao.gov.br/noticias/2013/07/research-and-markets-public-vs- private-healthcare-in-brazil-realities-of-drug-charges
    7. 7. • Generics are an increasing market • Medicine prices are regulated by CMED • ANVISA- grants marketing approvals to new drugs • Alternative channels to communicate with physicians include- remote detailing and special attention dedicated to physicians websites. • Sales representatives can make unlimited visits to doctors’ offices • Material gifts and trips from reps are prohibited • Promotion at point of sales
    8. 8. THREE KEY TRENDS AFFECTING BRAZIL’S MARKET LANDSCAPE • Innovation is declining in the retail segment • Outpatient therapies addressed by commoditized drugs, mainly branded generics • Generic players growing stronger • Innovators focus on niche markets or turn to careful investments with strong brands eg.Sanofi, Novartis, Pfizer
    9. 9. • On the public side, creation of an economic evaluation agency (CITEC), caused a barrier to product inclusion in funding programs • On private side, payers tending to avoid over-expenditure on complex therapies • Unmet medical needs in complex diseases favors innovative non- retail drugs • Migration of MNCs to non-retail arena • Technical differentiation of new products prevails over commercial aggressiveness of local companies Source: IMS Health, Pharmerging-Brazil
    10. 10. RUSSIA
    11. 11. CURRENT SCENARIO The Russian healthcare system is fully subsidized Spends 4.5% GDP on healthcare Doctors are among the lowest paid professionals The market is very volatile and lacks a highly developed infrastructure Foreign manufacturers dominate Most large pharmaceutical companies are localized with the help of a state program Up to 70% of the pharmaceutical market is paid for out-of-pocket by consumers Source: Cegedim Relationship management-Emerging market today & tomorrow
    12. 12. CURRENT SCENARIO Local manufacturers currently produce outdated, low cost drugs, and many do not meet GMP standards Market distribution: • Innovative products makes 20% of the market • Generics accounting for 60% • Traditional drugs 20% Prescription drugs have a 60% market share Most essential drugs are foreign, and the prices of everything on the EDL are regulated by the state Concerning compensation, pharmaceutical companies cannot accept gifts The only money they can accept is payment for clinical trials, educational activities, and scientific activities
    13. 13. FUTURE TRENDS Plans to let go of assets dragging down the budget figures The Ministry of Health will develop and approve standards for treatment Limited pharmaceutical sales reps’ access to doctors Market growth is expected to be within 15% in 2015
    14. 14. FUTURE TRENDS Defining patient registers All Russian manufacturers must comply with GMP standards Want to reduce its dependence on imported drug so international companies need to localize their effect Pharma 2020, whose goal is to have at least 50% of drugs made in Russia and 25% made by a Russian company
    15. 15. STRATEGIES For OTC, patients awareness through programs and ads seen on television, web sites, magazines, brochures, and educational stands for patients in outpatient clinics For registering drugs in Russia is very time-consuming, strategy of using several distributors Working with district managers and having qualified key account managers can smooth the difficulty of working with a government that is less accessible and less transparent
    16. 16. INDIAINDIA
    17. 17. India’s Healthcare System Indian healthcare sector is expected US $280 billion industry by 2020. Estimated to grow 14% annually. Struggling to meet the needs of its vast population, but government programmes and reforms in the health insurance industry should improve the situation. Rural India contains more than 100 million untreated people. Government is successfully pursuing its goal of providing 80% of the population with healthcare access in the next few years. last five years - addition of 15,000 health sub-centers & 28,000 nurses. No. of primary health centers has increased by 84%, taking the total number to 20,107.
    18. 18. The Pharmaceutical Market Third largest volume in the world. Ranks 14th in terms of value. Expected to reach US$55 billion in 2020. Key Challenges to Further Growth in Emerging Markets Lack of healthcare infrastructure Price pressure Local competition Lack of IP protection Challenging/nontransparent contracting and tenders Talent issues (e.g., recruitment, development, and retention) Compliance challenges Lengthy product registration processes Regulatory requirements Supply chain and distribution issues Competition from multinationals Source: Booz & Company analysis
    19. 19. Future Trends & Strategies Global pharma players can take advantage of a variety of options to maximize their investment in India. OTC sales are on the increase, offering opportunities to achieve high volumes and enhance pharma brands in India. Expertise in contract manufacturing & scrutiny around quality issues is driving significant improvement in manufacturing standards. Phase III trials are now strongest, Phase II and IV trials are expected to grow, as more companies start offering end-to-end services. Weak intellectual property laws. A clause that disallows patents for treatments that are not more efficacious than those already on the market. Global Pharma’s evolving business models and options in India
    20. 20. CHINA
    21. 21. CURRENT SCENARIO Healthcare spending : Below 5% Great Economic disparity Ambitious goal in 2009 : 90% insurance coverage in 3years China as imperative sales market: • Internal booming market • A strategic logistic location near Asia Pacific emerging markets • Market for delocalization of raw materials(antibiotic ,cephalosporins • a platform for research programme and innovative drugs. • Largest patent application country after USA . Annui model :Centralize the purchase of drugs to reduce price abuse and consequential cost Beijing allowed Annui province to introduce its blind bid and tender process. Prescribing institution allow 0% markup on drugs listed in EDL and purchase of this pharmaceuticals through two enveloped centrally controlled bid 1st envelope: Ensures technical and quality. 2nd envelope: Price focus. Shanghai model attempts to balance price quality and benefit. MNC and domestic impacted on profitability.(Decreased in 30% profitability)
    22. 22. CURRENT SCENARIO MNC expanding presence in china : But Domestic industry growth is faster Essential Drug List: Requires key account manager a skill to build relation with hospitals and government takes years Pharma Sales Rep  very few are detailed , high turnover , frequency of visit is regulated Sales rep as educator or medical science liason Greatest challenge is rotating system of physicians by government hence no accurate data base
    23. 23. FUTURE TRENDS Pharma markets: 2nd Largest market by 2015 1. Aging population. 2. Increased incidence of chronic disease. 3. Significant investments. Branded generics less lucrative to MNC’s Chinese physicians will loose bonuses. Slashing of whole sale price of drugs .
    24. 24. STRATEGIES China evolves without stability . Flexibility is vital in china. Diversification is key in china Doctor education assures long term success.

    ×